Millie
your market intelligence analyst
Search Results
173 results
Your search is now limited to «Costs» expert search.
CBC News (Canada) 09/21/2019 09:00
Purdue Pharma has filed for bankruptcy in the United States, but what does that mean for the lawsuits in Canada over the opioid crisis? The concern in Canada is that because of the U.S. bankruptcy filing, the assets at the centre of the lawsuit could be in jeopardy.
More from CBC News (Canada):
Guardian (United Kingdom) 09/19/2019 02:00
What cases is Purdue caught up in and who else is involved and what happens next? Here’s what you need to know. , the maker of the prescription painkiller OxyContin, has for bankruptcy in federal court. The move is part of a tentative it says will provide $10bn to resolve an avalanche of lawsuits against it by American cities, counties and states that Purdue for the deadly . But a group of states led by , and oppose the deal and want to take Purdue to trial in an effort to win bigger damages and what they is a greater measure of justice from the company and the billionaire members of the who own it.
More from Guardian (United Kingdom):
InsuranceNewsNet 09/16/2019 03:59
We are seeking monetary damages," He said expenses for fighting the opioid crisis are far-reaching, including the cost of public health, police and emergency services, and public education.
More from InsuranceNewsNet:
CNBC - Business 09/15/2019 23:29
OxyContin maker Purdue Pharma filed for Chapter 11 bankruptcy protection on Sunday.
More from CNBC - Business:
The Vox 09/14/2019 15:28
For reference, a 2017 study from the White House Council of Economic Advisers linked a year of the opioid crisis to $500 billion in economic losses.
More from The Vox:
A deal worth as much as $12 billion that's being negotiated between Purdue Pharma and its owners, and the state, local and tribal governments involved in national opioid litigation has the potential to shape efforts to reach a global settlement with other manufacturers, drug distributors and retailers in lawsuits consolidated before a federal judge in Cleveland.
More from Minneapolis Star-Tribune (United States):
Business Insider 09/12/2019 16:19
She says she's got a plan for everything: Criminal justice reform, breaking up tech giants, universal pre-K, student debt relief, and a tax on the wealthy. But on the cusp of the third Democratic primary debate in Houston, still doesn't have one on healthcare. Rival campaigns are taking notice that a frontrunner for the 2020 Democratic presidential nomination has been slow to release specifics about an animating issue for primary voters. Larry Levitt, the executive director of health policy at the Kaiser Family Foundation, said Warren's views gives her plenty of wiggle room to change her message as the primary goes on. She says she's got a detailed plan for everything: Criminal justice reform, breaking up tech giants, universal pre-K, stude.
More from Business Insider:
Newsday (United States) 09/10/2019 18:21
Cuomo noted New York already is part of a multistate lawsuit against the pharmaceutical industry to cover rising Medicaid costs associated with the opioid crisis.
More from Newsday (United States):
PR Newswire 09/10/2019 12:10
Industry analysts estimate the country's healthcare system incurred more than $215.7 billion in costs related to the opioid crisis from 2001 to 2017.
More from PR Newswire:
After years of litigation, after years of local trauma, costs and distress tied to the opioid epidemic, Yost was suddenly trying to deny them their right to recoup damages -- even as county residents continue to die from opioid overdoses.
More from Charlotte Observer (United States):
Federal Telemedicine News 09/09/2019 06:03
The Bipartisan Policy Center’s (BPC) https://bipartisanpolicy.org new report "Health in All Policies: Exploring the Role of Three Federal Departments in Influencing Health", recommends ways for Federal agencies to use the "Health in All Policies" (HiAP) approach to mitigate the impact of social determinants of health across all levels of federal policymaking to improve health outcomes.

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications